Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial

Autor: Catherine Jane Bale, Rachel Butler, S Waters, Angela C. Casbard, Sarah Moon, Andrew Foxley, Ramachandran Venkitaraman, Catrin Cox, Johnathan Joffe, Tracie-Ann Madden, Fouad S Alchami, Margherita Carucci, Robert H. Jones, Chris Twelves, Pavel Bezecny, Sacha J Howell

Publikováno v: Jones, R, Casbard, A, Carucci, M, Cox, C, Butler, R, Alchami, F, Madden, T-A, Bale, C, Bezecny, P, Joffe, J, Moon, S, Twelves, C, Venkitaraman, R, Waters, S, Foxley, A & Howell, S 2020, ' Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION) : a multicentre, randomised, controlled, phase 2 trial ', The Lancet Oncology, vol. 21, no. 3, pp. 345-357 . https://doi.org/10.1016/S1470-2045(19)30817-4

Background Capivasertib (AZD5363) is a potent selective oral inhibitor of all three isoforms of, the serine/threonine kinase, Akt. Akt inhibitors are anticipated to have maximal efficacy in combination with chemotherapy, targeted, or anti-hormonal dr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be3e1775f72f2c39bba92c189237cd97
https://pubmed.ncbi.nlm.nih.gov/32359499

Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia

Autor: Chalandon, Yves, Thomas, Xavier, Hayette, Sandrine, Cayuela, Jean-Michel, Abbal, Claire, Huguet, Françoise, Raffoux, Emmanuel, Leguay, Thibaut, Rousselot, Philippe, Lepretre, Stéphane, Escoffre-Barbe, Martine, Maury, Sébastien, Berthon, Céline, Tavernier, Emmanuelle, Lambert, Jean-François, Lafage-Pochitaloff, Marina, Lhéritier, Véronique, Chevret, Sylvie, Ifrah, Norbert, Dombret, Hervé, Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL)

Publikováno v: Blood, Vol. 125, No 24 (2015) pp. 3711-3719

In this study, we randomly compared high doses of the tyrosine kinase inhibitor imatinib combined with reduced-intensity chemotherapy (arm A) to standard imatinib/hyperCVAD (cyclophosphamide/vincristine/doxorubicin/dexamethasone) therapy (arm B) in 2

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::76ff7b8fa7c747ce8aaa642d7f259a20
https://doi.org/10.1182/blood-2015-02-627935

Determination of serum levels of imatinib mesylate in patients with chronic myeloid leukemia: validation and application of a new analytical method to monitor treatment compliance

Autor: Felipe Augusto Dörr, Israel Bendit, Ariane Julio Rivellis, Melissa Medrano Gomes, Dalton Alencar Fisher Chamone, Luciana Nardinelli, Vinicius Marcondes Rezende, Ariel Lais de Lima Costa, Mafalda Megumi Yoshinaga Novaes

Publikováno v: Revista Brasileira de Hematologia e Hemoterapia, Vol 35, Iss 2, Pp 103-108 (2013)
Revista Brasileira de Hematologia e Hemoterapia
Revista Brasileira de Hematologia e Hemoterapia, Volume: 35, Issue: 2, Pages: 103-108, Published: 2013
Revista Brasileira de Hematologia e Hemoterapia v.35 n.2 2013
Revista brasileira de hematologia e hemoterapia
Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron:ABHHTC

OBJECTIVE: The goal of this study was to monitor imatinib mesylate therapeutically in the Tumor Biology Laboratory, Department of Hematology and Hemotherapy, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (USP). A simple an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::985ffdeadcce6faeae1aea8ffb9af8d9
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842013000200011&lng=en&tlng=en

Voriconazole Therapeutic Drug Monitoring in Patients with Invasive Mycoses Improves Efficacy and Safety Outcomes

Autor: Saskia Bolay, Thierry Calandra, Oscar Marchetti, Andres Pascual, Thierry Buclin, Jacques Bille

Publikováno v: Clinical Infectious Diseases, vol. 46, no. 2, pp. 201-211

BACKGROUND: Voriconazole is the therapy of choice for aspergillosis and a new treatment option for candidiasis. Liver disease, age, genetic polymorphism of the cytochrome CYP2C19, and comedications influence voriconazole metabolism. Large variations

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c92cc71cb312fde4df31899e52221e0
https://doi.org/10.1086/524669

A phase Ib trial of LY2584702 tosylate, a p70 S6 inhibitor, in combination with erlotinib or everolimus in patients with solid tumours

Autor: Joel Miller, Antoine Hollebecque, Antoine Italiano, Karim A. Benhadji, Christophe Massard, Nadine Houede, Jean-Charles Soria, Ezra E.W. Cohen, Paul Westwood, Les H. Brail, William Bumgardner

Publikováno v: European Journal of Cancer
European Journal of Cancer, Elsevier, 2014, 50, pp.876--84. ⟨10.1016/j.ejca.2013.12.006⟩

Background LY2584702 tosylate (hereafter referred to as LY2584702) is an oral, selective ATP competitive inhibitor of p70 S6 kinase. Preclinical studies with LY2584702 demonstrated significant synergistic activity with erlotinib and everolimus. The p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8c3a7a2858a536425a05890e5690b8d2
https://pubmed.ncbi.nlm.nih.gov/24456794